Dynavax Technologies Corporation (DVAX) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlighted strong financial performance with increased net income and adjusted EBITDA, alongside disciplined expense management. The company is optimistic about HEPLISAV-B's market share growth and strategic vaccine programs. While there are concerns about the cost of the oral COVID vaccine program, the overall sentiment in the Q&A was positive with confidence in market growth and strategic execution. The raised guidance for HEPLISAV-B and share repurchase program also contribute to a positive outlook.
Key Financial Performance
Net Product Revenue from HEPLISAV-B $90 million in Q3 2025, representing a 13% increase year-over-year. The increase is attributed to strong commercial execution, market share expansion, and the differentiated clinical profile of HEPLISAV-B.
Total Revenues Approximately $95 million in Q3 2025, up 18% year-over-year. This growth is driven by the increase in HEPLISAV-B sales and overall market expansion.
HEPLISAV-B Gross Margin 84% in Q3 2025, consistent with expectations for gross margin in the low 80s percent for the year.
R&D Expenses $19 million in Q3 2025, up from $14 million in Q3 2024. The increase is due to pipeline advancements, particularly in the shingles program and the Department of Defense-funded plague program.
SG&A Expenses Approximately $40 million in Q3 2025, consistent with prior year levels (excluding proxy contest-related costs). This reflects disciplined financial management and high ROI investments.
GAAP Net Income $27 million in Q3 2025, compared to $18 million in Q3 2024. The increase is attributed to higher revenues and disciplined expense management.
Non-GAAP Adjusted EBITDA $36 million in Q3 2025, compared to $25 million in Q3 2024. The improvement is driven by increased revenues and operational efficiency.
Cash and Equivalents $648 million as of Q3 2025, down from $714 million at the end of 2024. The decrease is primarily due to the completion of a $200 million share repurchase program.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
HEPLISAV-B net product revenue: Generated $90 million in net product revenue this quarter, a 13% increase year-over-year. The product achieved a 46% U.S. adult hepatitis B vaccine market share, up from 44% in the prior year period. Retail segment market share grew to 63% from 55% last year.
Shingles vaccine program (Z-1018): Progressed into Part 2 of the Phase I/II study for adults aged 70 years and older. Top-line immunogenicity and safety results from Part 2 and 12-month follow-up data from Part 1 are expected in the second half of 2026.
Pandemic influenza adjuvant program: Completed Part 1 of the Phase I/II study, demonstrating high levels of seroconversion and seroprotection. Advancing selected formulations to Part 2 with data expected in 2026.
Plague vaccine program: Received $14 million in additional funding from the Department of Defense and completed enrollment in Part 1 of the ongoing Phase II trial.
Market share expansion for HEPLISAV-B: Achieved 46% total market share in the U.S. adult hepatitis B vaccine market, with a 63% share in the retail segment. The company aims for at least 60% market share by 2030.
COVID-19 oral vaccine candidate: Entered an exclusive license agreement with Vaxart for a Phase IIb COVID-19 oral vaccine candidate. The vaccine aims to provide systemic and mucosal immunity and disrupt the current vaccine market if successful. Top-line data is expected by the end of 2026.
Share repurchase program: Authorized a new $100 million share repurchase plan, bringing the total capital return to shareholders to $300 million, representing 25% of the current market capitalization.
Financial performance: Achieved $95 million in total revenues this quarter, an 18% year-over-year increase. Adjusted EBITDA improved to $36 million from $25 million in the prior year period.
Capital allocation strategy: Focused on deploying capital towards late-stage, highly synergistic assets like the Vaxart COVID-19 vaccine program while maintaining financial discipline.
Pipeline advancement: Progressed multiple clinical programs, including shingles, pandemic flu, and plague vaccines, towards key milestones in 2026.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market competition and market share growth: The company aims to achieve a 60% market share in the U.S. adult hepatitis B vaccine market by 2030, but faces competitive pressures and the need for sustained marketing investments to maintain and grow its position.
Regulatory hurdles: The company is engaging with the FDA to finalize the study protocol for a supplemental BLA for HEPLISAV-B in adults on hemodialysis, which could delay product expansion if not resolved promptly.
Pipeline development risks: Advancing multiple clinical programs, including shingles and pandemic flu vaccines, involves significant R&D expenses and the risk of not achieving desired clinical outcomes or regulatory approvals.
Economic uncertainties: The company’s financial performance and ability to execute share repurchase programs depend on maintaining strong revenue growth and managing expenses amidst broader economic uncertainties.
COVID-19 vaccine program risks: The success of the Vaxart oral COVID-19 vaccine program is uncertain, with key data readouts not expected until late 2026. The company has structured the deal to mitigate risks, but future investments depend on Phase IIb results.
Supply chain and operational challenges: The company must ensure consistent production and distribution of HEPLISAV-B and other pipeline products to meet market demand, which could be impacted by supply chain disruptions or operational inefficiencies.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
HEPLISAV-B Market Share: The company aims to achieve at least 60% total market share in the U.S. adult hepatitis B vaccine market by 2030, supported by expanding retail adoption, sustained IDN performance, and growing awareness of the ACIP universal recommendation.
Shingles Vaccine Program: The shingles vaccine program has progressed to Part 2 of the Phase I/II study focused on adults aged 70 years and older. Top-line immunogenicity and safety results from Part 2 and 12-month follow-up data from Part 1 are expected in the second half of 2026. The company plans to explore strategic partnerships based on these results.
Vaxart Oral COVID-19 Vaccine: Dynavax has entered into an exclusive license agreement for Vaxart's oral COVID-19 vaccine program, currently in a Phase IIb safety and efficacy study. Top-line data is expected by the end of 2026, with the potential to proceed to Phase III development based on results and regulatory feedback.
Pandemic Influenza Adjuvant Program: The program has completed Part 1 of the Phase I/II study, demonstrating high levels of seroconversion and seroprotection. Part 2 is advancing, with top-line immunogenicity and safety data expected in 2026.
Plague Vaccine Program: The Department of Defense-funded program has received $14 million in additional funding and completed enrollment in Part 1 of the ongoing Phase II trial.
HEPLISAV-B Revenue Guidance: The company expects HEPLISAV-B net product revenue to be in the range of $315 million to $325 million for the full year 2025, with double-digit annual growth in net product sales projected through 2030.
Adjusted EBITDA Guidance: Dynavax has raised its adjusted EBITDA guidance for 2025 to at least $80 million, an improvement from the prior guidance of $75 million.
R&D Expense Outlook: R&D expenses are expected to steadily increase through 2026, driven by the advancement of mid- to late-stage clinical assets, including the shingles program and the Vaxart oral COVID-19 vaccine program.
Share Repurchase Program: The company has authorized a new $100 million share repurchase program, expected to be executed within the next 12 months, bringing the total capital return to shareholders to $300 million.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: Dynavax announced the authorization of a new $100 million share repurchase plan. This program reflects the company's confidence in its long-term growth and commitment to enhancing shareholder value. The program is expected to be executed within the next 12 months. This follows the completion of a previous $200 million share repurchase program earlier in the year, which retired approximately 17 million shares. In total, the cumulative capital return to shareholders will amount to $300 million, representing approximately 25% of the company's current market capitalization.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Why license a COVID vaccine today? Do you think a successful oral option can return the overall market to growth, particularly with more stringent recent labeling?
A:The CEO explained that licensing a COVID vaccine is a strategic opportunity that fits their capabilities well. They believe an improved vaccine with better delivery mechanisms and efficacy can help grow the market, which has room for growth compared to other vaccines like flu. The study is adequately powered with 5,400 subjects to demonstrate improvement over the comparator mRNA vaccine. They aim to achieve better efficacy, tolerability, and reduction in symptomatic infection and hospitalizations over a longer period.
Q:Do you feel like you are in a position to be able to do registrational studies for both the shingles program and the oral COVID-19 pill at the same time if both move forward?
A:The CEO confirmed they are capable of conducting registrational studies for both programs simultaneously. They will manage the staging of activities and organizational growth to execute appropriately.
Q:What do you need to see to advance the oral COVID vaccine program? Is non-inferior performance with oral delivery enough?
A:The CEO stated that the trial is designed to show improvement head-to-head against an mRNA vaccine. Non-inferior performance is not enough; the goal is to drive a better option forward. Secondary endpoints could also provide meaningful evidence.
Q:Can you give some sense of the cost of development for the oral COVID vaccine program, should you opt in? How much would that change your profitability profile?
A:The CFO mentioned that a placebo-controlled efficacy study would be required, which would come with a significant cost. However, they plan to manage profitability through growth in HEPLISAV-B and strategic partnerships for shingles, especially outside the U.S.
Q:How dramatic is the seasonality impact on HEPLISAV-B revenue in Q4?
A:The Chief Commercial Officer noted that seasonality, including the holidays, slows demand in Q4. However, as retail grows in adult immunizations, specifically hepatitis B, they expect stronger Q4 performance over time.
Q:What have you seen to suggest strong serum immunity as well as mucosal immunity in the next-gen oral COVID vaccine?
A:The CEO noted that the second-gen construct has shown improved immunogenicity in the norovirus trial, which they believe will translate to COVID. While systemic immunity (IgG) may not match injectable vaccines, the efficacy study will provide the necessary insights.
Q:Why was the study size for the oral COVID vaccine reduced, and will the current administration cause issues for further development?
A:The CEO explained that the reduction in trial size was a blanket decision related to trials using mRNA. BARDA continues to fund the enrolled patients, and the study is well-powered at 5,400 subjects. They do not anticipate issues for further development.
Q:How confident are you in achieving a 60% market share for HEPLISAV-B by 2030, and what are the key drivers?
A:The CEO expressed confidence, citing steady progress in market share (currently 46%) and growth in the retail segment, where they have the highest share. They expect continued share increases and volume shifts to retail to drive growth to 60% by 2030.
Q:Has Part 2 of the shingles study (Z-1018) started, and what is the timeline for results?
A:The CEO confirmed that Part 2 of the shingles study has started, with patients dosed in Q3. Results are expected in the second half of next year.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the cost specifics of the oral COVID vaccine program, providing only general comments about managing profitability. Additionally, they did not provide detailed data on the serum immunity of the next-gen oral COVID vaccine, instead emphasizing the need for efficacy studies to gain insights.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ACIP recommendation
Affairs Donn
BLA HEPLISAV
BLA filing
Communications statement
Defense award
Defense funding
Donn VP
Donn progress
FDA study
FDA vaccine
HEPLISAV adult
HEPLISAV care
HEPLISAV focus
HEPLISAV profile
HEPLISAV utilization
IDN awareness
II study
II trial
Phase IIb
activation
adult HEPLISAV
area
benefit
capital term
deal
end Phase
gain segment
head
immunization
immunogenicity safety
license agreement
line immunogenicity
market HEPLISAV
need
program Phase
retail IDN
review
shareholder value
term opportunity
thousand
DVAX Transcript
Dynavax Technologies Corporation (DVAX) Q3 2025 Earnings Call Transcript
Positive11-5
The earnings call highlighted strong financial performance with increased net income and adjusted EBITDA, alongside disciplined expense management. The company is optimistic about HEPLISAV-B's market share growth and strategic vaccine programs. While there are concerns about the cost of the oral COVID vaccine program, the overall sentiment in the Q&A was positive with confidence in market growth and strategic execution. The raised guidance for HEPLISAV-B and share repurchase program also contribute to a positive outlook.
Dynavax Technologies Corporation (DVAX) Q2 2025 Earnings Call Transcript
Positive8-7
The earnings report reveals strong financial performance with record HEPLISAV-B revenue and increased market share. The company provides optimistic full-year guidance and demonstrates disciplined expense management. The Q&A session highlights strategic focus on retail market growth and successful share repurchase program execution. Despite a decrease in cash reserves due to buybacks, the financial health remains robust. The lack of large orders indicates sustainable growth, and the company's alignment with DoD on the plague vaccine program is positive. Overall, the sentiment is positive with potential for a 2% to 8% stock price increase.
Dynavax Technologies Corporation (NASDAQ:DVAX) Q1 2025 Earnings Call Transcript
Unknown5-7
The earnings call presents mixed signals: strong HEPLISAV-B sales and share repurchase are positive, but EPS miss, regulatory risks, and economic uncertainties are concerns. The Q&A reveals cautious management, especially on guidance and Shingles program, suggesting market uncertainty. Market cap indicates moderate volatility, leading to a neutral prediction.
Earnings call transcript: Dynavax Q1 2025 misses EPS forecast, stock dips
Unknown5-6
The earnings call summary presents mixed signals. Strong financial performance with record HEPLISAV-B revenue and increased market share suggests positive growth. However, significant GAAP net loss and financial risks raise concerns. The share repurchase plan and improved gross margins are positive, but the guidance was not raised despite confidence, indicating caution. The Q&A highlighted potential FDA challenges and management's avoidance of specifics, adding uncertainty. With a market cap of $1.49 billion, the stock's reaction is likely neutral, reflecting both positive growth prospects and existing financial and regulatory challenges.
DVAX Slides
DVAX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
